Slingshot members are tracking this event:

Dynavax and AstraZeneca Ammend their Agreement for Asthma Drug Candidate

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details In a previously reported Phase 1a study of the safety of 4 weekly doses of AZD1419 compared to placebo in 45 healthy volunteers, ascending doses were well tolerated with no serious adverse events observed in treated subjects. Additional endpoints assessing pharmacodynamics were met, with dose-dependent induction of interferon-regulated genes in sputum and blood cells.

Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 19, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Research Collaboration, License Agreement, Strategic Priorities, Vaccines, Immuno-oncology, Asthma, Phase 2a, Azd1419